Neurocrine to buy Soleno Therapeutics for $2.9 billion
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.
Key Points
- Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.
- Reported by CNBC.
- This is a Finance & Markets story with significant implications.
Full Details
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.
Why It Matters
This Finance & Markets development reported by CNBC has potential ripple effects across the sector. Stakeholders should monitor how this situation evolves in the coming weeks. The broader implications for policy and industry players remain to be seen.
Get stories like this delivered daily
AI-curated news, personalized to your interests. Zero noise.
Start 7-Day Free Trial →More in Finance & Markets
U.S., Iran study ceasefire plan as Trump's 'hell' warning nears deadline
The United States and Iran on Monday were weighing the framework of a plan to end their five-week conflict, even as Tehran pushed back against pressure.
U.S. ends probe into Tesla remote driving feature after software updates
The U.S. National Highway Traffic Safety Administration announced on April 6, 2026 that it has closed its investigation into Tesla’s “Actually Smart Summon” remote‑driving feature, which is installed in about 2.59 million vehicles. The regulator said the probe was ended because the incidents linked to the feature were low‑speed, involved no injuries or fatalities, and occurred at a very low frequency. Tesla addressed the identified problems through a series of over‑the‑air software updates that
Oracle names Schneider Electric's Maxson as CFO amid soaring AI spending
Oracle on Monday appointed Hilary Maxson as chief financial officer, tapping an executive with experience in infrastructure and energy.
Tesla is down sharply in 2026. JPMorgan sees the stock falling another 60%
"We ... advise investors approach TSLA shares with a high degree of caution," analyst Ryan Brinkman said in a note.